Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictors of Opioid-Induced Respiratory Depression
NCT02473354Phase 1Completed
- Sponsor
- Duke University
- Start
- Apr 2015
- Primary completion
- Apr 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, single-arm trial of remifentanil in respiratory depression, sponsored by Duke University. Primary endpoint: Hypercapnic Ventilatory Response gradient at 30 minutes. Started Apr 2015; status: completed.
02
Drugs
remifentanil
03
Conditions
respiratory depression
Beyond the preview
Go deeper on NCT02473354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02473354.